MAHESWARAN et al. Appl. No. 10/646784

- 2 -

group I) would likely be coextensive with a search of tumor inhibiting pharmaceutical compositions comprising an effective tumor inhibiting amount of MIS and interferon that results in decreased side effects (as encompassed by the claim of group II). Thus, Applicants respectfully request that the restriction requirement be reconsidered and withdrawn.

With respect to the election of species requirement, Applicants respectfully remind the Examiner that, upon allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all of the limitations of the allowed generic claim.

It is not believed that extensions of time are required beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Consideration and allowance of all pending claims are respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham Attorney for Applicants

Registration No. 50,437

Date: <u>AUG. 21, 2006</u>

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

563939_1.DOC